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Abstract With the improvement of long-term cancer survival
rates, growing numbers of female survivors are suffering from
treatment-related premature ovarian insufficiency (POI).
Although pre-treatment embryo and oocyte storage are effec-
tive fertility preservation strategies, they are not possible for
pre-pubertal girls or women who cannot delay treatment. In
these cases, the only available treatment option is ovarian
cortex cryopreservation and subsequent re-implantation. A
32-year-oldwoman had ovarian cortex cryopreserved 10 years
previously before commencing high-dose chemotherapy and
undergoing a haematopoietic stem cell transplant for recurrent
adult Wilms tumour, which resulted in POI. She underwent
laparoscopic orthotopic transplantation of cryopreserved ovar-
ian cortex to the original site of biopsy on the left ovary. She
ovulated at 15 and 29 weeks post-re-implantation with AMH
detectable, then rising, from 21 weeks, and conceived
naturally following the second ovulation. The pregnancy
was uncomplicated and a healthy male infant was born by
elective Caesarean section at 36+4 weeks gestation. This is
the first report of ovarian cortex re-implantation in the UK.
Despite the patient receiving low-risk chemotherapy prior to
cryopreservation and the prolonged tissue storage duration,
the re-implantation resulted in rapid restoration of ovarian
function and natural conception with successful pregnancy.
Keywords Ovarian cortex re-implantation . Fertility
preservation . Premature ovarian insufficiency . AMH
Introduction
The developments in cancer treatments over the last few de-
cades have resulted in greatly increasing numbers of survivors.
However, this has come at a cost, with many patients suffering
long-term adverse effects of their life-saving treatment. The ova-
ries are particularly susceptible to damage by chemotherapy and
radiotherapy with the type and dose of therapy and age of the
patient influencing the extent of the injury [1, 2]. Loss of fertility
is a major concern for young women facing potentially
sterilising treatment [3]; one study found that almost three quar-
ters of female cancer survivors of reproductive age have con-
cerns regarding infertility and that survivors with irregular men-
ses reported a lower quality of life than those with regular men-
strual cycles [4]. Recent years have consequently seen signifi-
cant developments in approaches to preserve fertility in those
women and girls who are at risk of undergoing treatment-related
premature ovarian insufficiency (POI) [5].
Embryo and oocyte cryopreservation are now established
fertility preservation strategies [2, 5]; however, these are not
appropriate in pre-pubertal girls, and in adult women the
Capsule The first re-implantation of cryopreserved ovarian cortex in the
UK has resulted in restoration of ovarian function and natural conception,
with detectable and rising AMH levels.
* C. E. Dunlop
Cheryl.Dunlop@ed.ac.uk
1 Simpson’s Centre for Reproductive Health, Royal Infirmary of
Edinburgh, Edinburgh EH16 4SA, UK
2 MRC Centre for Reproductive Health, University of Edinburgh,
Edinburgh EH16 4TJ, UK
3 Centre for Integrative Physiology, University of Edinburgh,
Edinburgh EH8 9XD, UK
4 Beatson West of Scotland Cancer Centre, Glasgow G12 0YN, UK
5 Tissue and Cells Services, Scottish National Blood Transfusion
Service, Edinburgh EH17 7QT, UK
6 Royal Hospital for Sick Children, Edinburgh EH9 1LF, UK
J Assist Reprod Genet
DOI 10.1007/s10815-016-0805-2
necessary ovarian stimulationmay delay the start of cancer treat-
ment. Ovarian tissue cryopreservation remains the only option
in these situations. This approach was first validated in a large
animal model [6] and has been offered to selected patients since
1993 [7]. The first human live birth as a result of ovarian cortex
re-implantation was reported over a decade ago [8], and since
then, there have been at least 60 live births described globally
[9]. Yet, it is still regarded as an experimental technique with an
uncertain success rate. We here describe the first human ovarian
cortex re-implantation in the UK and report resumption of ovar-
ian function resulting in a natural conception and pregnancy.
Methods
The patient was first referred to the Fertility Preservation ser-
vice in Edinburgh, UK, at 22 years of age for discussion of
ovarian cortex cryopreservation. She was a nulliparous, non-
smoker with a normal body mass index and a past medical
history of juvenile rheumatoid arthritis. She had presented
with a right-sided abdominal mass at 21 years old and diag-
nosed with a stage 1 adult Wilms tumour of the right kidney.
Following a right nephrectomy and adrenalectomy, she re-
ceived adjuvant chemotherapy in the form of 5 cycles of vin-
cristine and actinomycin D, following which her menstrual
cycles continued. However, 3 months later, she had a recur-
rence of the tumour in the right renal bed, and a CT scan
detected multiple pulmonary metastases. As the proposed
treatment was deemed to be gonadotoxic, she was counselled
regarding fertility preservation options. She elected for ovari-
an cortex cryopreservation, and 5 months following initial
chemotherapy, she underwent laparoscopic removal of 18 bi-
opsies of ovarian cortex from the left ovary with subsequent
slow freezing [6] and long-term storage in the vapour phase of
liquid nitrogen, with informed consent and ethical committee
approval of the protocol. A piece of ovarian cortex sent for
histopathological analysis showed the presence of a single
primordial follicle, a corpus albicans, normal ovarian stroma
and no evidence of malignant contamination (Fig. 1).
Subsequently, she received curative treatment consisting of
chemotherapy comprising carboplatin (area under the curve
(AUC) 10; 3 doses), etoposide (200 mg/m2; 9 doses), cyclo-
phosphamide (500 mg/m2; 12 doses) and doxorubicin (30 mg/
m2; 6 doses), resection of the recurrent tumour including partial
hepatectomy, an autologous peripheral blood stem cell trans-
plant (PBSCT) with pre-conditioning using high-dose melpha-
lan (200 mg/m2; 1 dose) and radiotherapy. She received radio-
therapy to the whole of both lungs (with a boost to the residual
tumour sites) and to the right flank. The lower (inferior) border
of the flank radiotherapy was the inferior edge of L2, and it
extended from midline to the right lateral abdominal wall. The
total dose to this region was 3000 cGy with the estimated dose
to the right ovary being 100 cGy. The uterus was not in the
field of radiation. This was followed by bilateral lower lobe
resection of both lungs, with pathology showing no residual
disease. These treatments induced POI, which was diagnosed
by the presence of amenorrhoea, elevated gonadotrophins (fol-
licle stimulating hormone (FSH) >100 IU/L and LH 53.1 IU/L)
and low estradiol (E2; <70 pmol/L). Similar hormonemeasure-
ments were obtained on repeat sampling, and hormone re-
placement therapy was commenced in the form of a combined
oral contraceptive pill (COCP).
At 32 years of age, the patient was disease-free and in a
stable relationship, and requested re-implantation of her stored
ovarian cortex with the aim of achieving a pregnancy. She had
continued on COCP for hormone replacement in the interim.
Given her medical history, she was reviewed in the pre-
conceptual obstetric clinic and underwent cardio-respiratory
assessment with an exercise tolerance test to assess her ability
to carry a pregnancy. Pelvic ultrasound showed a normal uter-
us. Laparoscopic orthotopic transplantation of thawed ovarian
cortex was performed in May 2015 (Fig. 2). The site of previ-
ous resection of ovarian cortex was clearly visible on the left
ovary (Fig. 2a), with both ovaries atrophic but the pelvis oth-
erwise normal with no adhesions. The tissue was thawed using
a previously reported and validated protocol [6, 10]. A longi-
tudinal incision along the left ovary was carried out and eight
pieces of cortex (each approximately 1 cm × 1 cm × 0.5 cm)
were then introduced onto the resultant cut ovarian surface,
which was vascular but did not bleed actively. The tissue pieces
were adhered to the ovary using fibrin sealant without suturing.
The patient stopped her COCP at the time of the operation.
Results
The patient was followed up post-operatively with regular
transvaginal ultrasound scans and serial measurement of se-
rum gonadotrophins, E2 and anti-Mϋllerian hormone (AMH)
(Fig. 3). SerumAMHwas measured using an automated assay
Fig. 1 Biopsy of ovarian cortex removed at the time of ovarian cortex
cryopreservation demonstrating a single primordial follicle with two
nucleoli surrounded by normal ovarian stroma. The patient had already
received non-sterilising chemotherapy prior to this biopsy
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(Roche Elecsys, sensitivity 0.07 pmol/L). Due to problematic
climacteric symptoms, low-dose hormone replacement thera-
py was recommenced 5 weeks postoperatively, with 1 mg oral
E2 daily. Her gonadotrophins fell, and a follicle of mean di-
ameter 14 mm on the left ovary was observed 15 weeks post-
operatively, at which time FSH was 11.2 IU/L, LH 13.4 IU/L
and E2 891 pmol/L. She subsequently ovulated spontaneously
with a confirmatory serum progesterone of 27.9 nmol/L 7 days
later and menses a further week later. Hormone replacement
therapy (HRT) was discontinued, but her menopausal symp-
toms returned; therefore, it was restarted 6 weeks later. She
had a further spontaneous ovulation at 29 weeks postopera-
tively (peak E2 891 pmol/L followed by progesterone
34.9 nmol/L) (Fig. 4a and b). Natural conception occurred,
and a single, viable intrauterine pregnancy was confirmed on
transvaginal ultrasound scanning at 7 weeks gestation
Fig. 3 Serum hormones were
measured following re-
implantation, with day 0 being the
day of re-implantation. a Serum
gonadotrophin (follicle
stimulating hormone (FSH),
luteinising hormone (LH) and
estradiol (E2) levels. The grey




following the two E2 peaks
denoted by black arrows,
confirming ovulation. b Serum
anti-Mϋllerian hormone (AMH)
levels rose steadily from 21weeks
post-re-implantation
Fig. 2 Laparoscopic orthotopic ovarian cortex re-implantation. a The
atrophic native left ovary with scarring from previous ovarian cortical
biopsy clearly visible. b A longitudinal incision was made along the left
ovary resulting in a vascular surface. cEight pieces of ovarian cortex were
placed inside the native left ovary and adhered with fibrin sealant
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(Fig. 4c), with a corpus luteum visible on the left ovary. AMH
became detectable at 21 weeks post-re-implantation and rose
progressively thereafter, although remaining low.
The pregnancy proceeded routinely, with normal ultra-
sound scans at 12, 20 and 28 weeks gestation. An elective
Caesarean section was performed for maternal reasons (large-
ly related to shortness of breath) at 36+4 weeks gestation with
the delivery of a healthy male infant weighing 3.01 kg. Apgar
scores were 9 at 1 min and 9 at 5 min, and cord blood gases
were normal.
Discussion
In this case report, we describe the first incidence of ovarian
cortex re-implantation with natural conception and successful
pregnancy in the UK. The ovarian tissue had been exposed to
non-sterilising chemotherapy, had been cryopreserved for
10 years and demonstrated an apparent reduced ovarian re-
serve on pathology. Yet, ovulation was detected within
15 weeks of the re-implantation, and a viable pregnancy was
achieved after the second ovulation. That the pregnancy has
occurred from a follicle within the grafted tissue appears high-
ly likely due to the patient suffering POI, diagnosed clinically
and biochemically, for 9 years prior to re-implantation, the
presence of a dominant follicle at the site of re-implantation
and a corresponding corpus luteum following ovulation.
Although the patient reported initial improvement of men-
opausal symptoms in the weeks following replacement, HRT
was later required for symptom relief, and it is notable that
both ovulations occurred whilst taking oestrogen-only HRT.
Oestrogen replacement increased the ovulation rate (and pos-
sibly pregnancy rate) in a randomised placebo-controlled trial
in womenwith POI [11], with the effect confined to those with
lower FSH concentrations during oestrogen treatment, proba-
bly reflecting less complete cessation of ovarian activity.
Further RCTs are required to investigate the efficacy of this
approach. Serum AMH remained undetectable following re-
implantation for 20 weeks using a highly sensitive assay with
limit of detection 0.07 pmol/L (0.01 ng/mL), then rose steadi-
ly over the next months until pregnancy. Thus, AMH
remained undetectable until after the first ovulation but was
thereafter consistently detectable, albeit at very low levels
with a concentration of 1.8 pmol/L (0.25 ng/mL) at the time
of conception. Using older assays, AMH has previously been
reported to be generally undetectable post-re-implantation and
therefore has not been considered valuable in monitoring
ovarian function [12–14]. The present result therefore indi-
cates that AMH may be of value in assessing the duration of
function of ovarian transplants but requires the use of new,
sensitive assays, although it must be recognised that AMH is
not predictive of fecundability in young women [15].
Our findings are in keeping with those of the other main
centres where ovarian cortex cryopreservation is performed
[9, 14, 16]. A study of 60 cases of re-implantation worldwide
reported the restoration of ovarian function in 93 % of pa-
tients, with a correlation seen between resumption of menses
and number of follicles in the re-implanted tissue [14], whilst a
case series of 95 re-implantations performed by the
FertiPROTEKT network reported ovarian activity at 1 year
after replacement in 63 % of recipients with POI [16]. A pe-
riod of 3.5 to 6.5 months is generally observed before FSH
falls and E2 rises [14]. Conception rates of 29–33% have been
reported, with 75–82.5 % of these pregnancies resulting in a
live birth [9, 16]. Furthermore, natural conception has oc-
curred in more than half of the cases, as here, highlighting that
assisted reproductive techniques are not necessary for most
women [14]. An alternative approach is repeated cycles of
ovarian stimulation and embryo cryopreservation [17] al-
though this is very invasive and costly and therefore of limited
application. The great majority of these pregnancies have
occurred following slow freezing of the ovarian cortical
pieces [9]; however, a recent study indicated that vitri-
fication may have advantages [18] and, indeed, two
Fig. 4 Transvaginal ultrasound scan images post-re-implantation. a Two
antral follicles on the left ovary seen at 29 weeks postoperatively. The
larger follicle had a mean diameter of 15 mm and ovulation was
confirmed by a progesterone rise 1 week later. b Longitudinal view of
the uterus at 29 weeks post-re-implantation demonstrating an endometrial
thickness of 7.9 mm. c Single viable intrauterine pregnancy at 7+3 weeks
gestation by crown-rump length (CRL) measurement (white arrow). The
yolk sac is denoted by the black arrow. A corpus luteum was seen on the
left ovary
J Assist Reprod Genet
pregnancies following re-implantation of vitrified ovari-
an cortex have been reported [19].
This case illustrates that cryopreserved ovarian tissue can
be stored for long periods of time with maintenance of follicle
growth potential and oocyte viability. The longest reported
duration of storage resulting in pregnancy is 11 years, in a
young woman with sickle cell anaemia whose ovarian tissue
was cryopreserved aged 14 [20]. In the present case, she had
previously received chemotherapy with vincristine and acti-
nomycin D which have very low gonadotoxicity [21], but it is
striking that pathological analysis of a biopsy of ovarian cor-
tex showed the presence of only one primordial follicle de-
spite her young age at that time. Assessment of ovarian re-
serve by ultrasound or serum AMH was not possible at that
time. Furthermore, re-implantation of ovarian tissue results in
loss of the majority of follicles within the tissue [22].
However, it is well recognised that the distribution of follicles
within the ovary in not even [23–25].
Preceding chemotherapy may affect graft function. The
time to first ovulation in this case was more rapid than is
generally observed in patients who had received chemothera-
py prior to cryopreservation (less than 4 months in this case
vs. 5.5–6.5 months [14]). This may not be related to her pre-
vious treatment; the rate of follicle activation increases with
age and falling primordial follicle pool. The effect of cytotoxic
treatments on ovarian reserve is variable and often difficult to
predict, particularly as chemotherapy regimens frequently
comprise a combination of drug classes. The alkylating agents
used in her subsequent treatment, such as cyclophosphamide
and melphalan (which are likely to have contributed to our
patient’s POI, following her treatment for recurrence), are
among the most toxic classes of chemotherapeutic agents
[1]. However, a recent detailed analysis of childhood cancer
survivors treated with chemotherapy without any possible ef-
fect of radiotherapy on gonadal function showed a risk of loss
of fertility only with the highest doses of alkylating agent in
females [26]. Furthermore, women who undergo a bone mar-
row transplant, as in this patient, are at extremely high risk of
POI due to the requirement for highly toxic pre-conditioning
regimens [27]. Previous chemotherapy is therefore important
to consider when planning any form of fertility preservation
procedure, with recent therapy potentially resulting in reduced
viability of oocytes and in the longer term resulting in loss of
ovarian reserve. However, this case highlights the likely im-
portance of the patient’s young age (22 years old at tissue
storage) and thus oocyte quality over low ovarian reserve in
predicting successful conception. Indeed, the FertiPROTEKT
case series demonstrated that re-implantation surgery was
more successful in those patients who had their tissue cryo-
preserved at younger ages [16].
With regard to the surgical approach to re-implantation,
several orthotopic strategies have been used (reviewed in
[14]). In this case, we performed a similar procedure to that
described by Sanchez-Serrano et al. [28] whereby the cortical
pieces were inserted into a remaining ovary next to the me-
dulla and sealed in place with a fibrin sealant. The pieces can
also be sutured to the medulla, or placed in a subcortical area,
although this was not performed here due to very high tissue
friability and the availability of highly effective fibrin sealant.
Another technique, required if the patient has no remaining
ovaries, is the placing of ovarian pieces into a peritoneal win-
dow, preferably a vascular area, with the use of a sealant to
keep the pieces adhered to the pelvic wall. Heterotopic re-
implantations have also been performed. This method of
transplantation has some advantages over orthotopic trans-
plantation, including easier access for monitoring of graft
function (reviewed in [14]); however, only one pregnancy
has been reported as a result of the use of a heterotopic site
(where the anterior abdominal wall was used) [29].
The average lifespan of ovarian tissue grafts appears to be
4–5 years [14] with much longer duration being reported in
some women [13]. Five women have delivered at least twice
from one re-implantation procedure to date [9]. Long-term
ovarian function, comprising both fertility and hormone pro-
duction can therefore be achieved; the latter is increasingly
recognised to be of importance in the light of long-term ad-
verse health effects of POI [30]. In this patient, ovarian func-
tion will be monitored post-pregnancy to assess the duration
of the grafts, and half the stored tissue remains cryopreserved
allowing the possibility of one or more further replacements.
This case therefore adds to the growing evidence that ovarian
tissue cryopreservation and later re-implantation are an impor-
tant component of the fertility preservation repertoire, with the
potential for restoration of fertility without the need for IVF
and expensive medical interventions, and with the additional
possibility of provision of long-term hormone production.
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